CPI-613 (devimistat)
Cancer (unspecified intractable forms)
Pre-clinicalActive
Key Facts
Indication
Cancer (unspecified intractable forms)
Phase
Pre-clinical
Status
Active
About Cornerstone Pharmaceuticals (2)
Cornerstone Pharmaceuticals is a private, pre-revenue biotech focused on metabolic oncology, a field targeting the unique energy metabolism of cancer cells. Its core asset is CPI-613 (devimistat), a mitochondrial inhibitor in preclinical combination testing, while it recently divested its glutaminase inhibitor CB-839 (telaglenastat). The company's strategy hinges on demonstrating that disrupting cancer cell metabolism can treat aggressive, recurrent cancers and potentially synergize with existing therapies, though it faces significant clinical and competitive risks inherent to novel oncology pathways.
View full company profile